Profund Advisors
AVLN icon

Profund Advisors’s Avalyn Pharma AVLN Stock Holding History

Profund Advisors’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$668K Buy
+23,433
New +$756K 0.02% 487

Other funds holding AVLN

Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Lewis Asset Management
Lewis Asset Management Lafayette, California $294M AUM 25.62% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Manchester Capital Management
Manchester Capital Management Manchester, Vermont $736M AUM 20.83% 1-Year Est. Return

Profund Advisors's AVLN Position: Q3 2026 in Review

Profund Advisors opened a new position in Avalyn Pharma (AVLN) in Q3 2026: 23,433 shares worth $668K. The stake represents 0.02% of the portfolio and ranks #487 among its holdings.

23 funds tracked by Wall St. Rank hold AVLN as of Q3 2026.

  • Profund Advisors held 23,433 shares of Avalyn Pharma worth $668K as of Q3 2026.
  • Avalyn Pharma was a new Profund Advisors position in Q3 2026.
  • Avalyn Pharma made up 0.02% of Profund Advisors's portfolio in Q3 2026, its #487 holding.
  • 23 funds tracked by Wall St. Rank held Avalyn Pharma as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.